Amanda Cabral dos Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amanda Cabral dos Santos has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Marcelo Gerardin Poirot Land
Postgraduate Program in Internal Medicine & Pediatric and Maternal Health Universidade Federal do Rio de Janeiro (UFRJ) Rio de Janeiro Brazil
3 shared publications Elisangela C Lima
School of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
2 shared publications- Elisangela Costa Lima
Universidade Federal do Rio de Janeiro, Brazil
1 shared publication Elisangela da Costa Lima-Dellamora
Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
1 shared publicationJulia Maria Bispo dos Santos
Carlos Chagas Filho Biophysics Institute Federal University of Rio de Janeiro Rio de Janeiro Brazil
1 shared publicationKelly Oliveira Santos
Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
1 shared publication
Latest Publications
- Open Access
- 24 August 2021
- Published by Wiley in Cancer Reports
- Vol. 5 (8) , e1533
L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study
Background: The survival of children with acute lymphoblastic leukemia (ALL) has improved due to changes in the treatment and the disease diagnosis. A significant advance was the incorporation of asparaginase. However, hypersensitivity reactions are a common cause of early discontinuation of this drug.Aim: The proposed study aims to evaluate early interruptions and the influence of the number of asparaginase doses effectively administered on the prognosis of patients with ALL.Methods and Results: An observational cohort study was carried out, with retrospective data collection, in medical records. The prognostic variables indicated in the protocol applied were used, and the principal outcomes were 5 years event‐free survival (EFS) and 5 years of overall survival (OS) probability. Statistical analyzes were performed using SPPS 20.0 and R. In Cox's proportional hazards model for EFS and OS, variables of prognostic importance (n = 126 children) were: high‐risk group (HGR), by the protocol classification, and less than 10 doses of asparaginase. The increased risk of events and death in HGR, who did less than 10 doses, was 3.6 and 7 times, respectively. The study did not show statistical significance for the number of asparaginase doses in patients who were not at high risk.Conclusions: We demonstrated that the early interruption of asparaginase treatment could negatively impact the prognosis of patients with ALL, especially HGR, reinforcing the need for careful diagnosis of reactions and the availability of alternative types of asparaginase.
- 24 August 2021
- Published by Wiley in Cancer Reports
- Vol. 5 (8) , e1533
Open AccessL‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study
Background: The survival of children with acute lymphoblastic leukemia (ALL) has improved due to changes in the treatment and the disease diagnosis. A significant advance was the incorporation of asparaginase. However, hypersensitivity reactions are a common cause of early discontinuation of this drug.Aim: The proposed study aims to evaluate early interruptions and the influence of the number of asparaginase doses effectively administered on the prognosis of patients with ALL.Methods and Results: An observational cohort study was carried out, with retrospective data collection, in medical records. The prognostic variables indicated in the protocol applied were used, and the principal outcomes were 5 years event‐free survival (EFS) and 5 years of overall survival (OS) probability. Statistical analyzes were performed using SPPS 20.0 and R. In Cox's proportional hazards model for EFS and OS, variables of prognostic importance (n = 126 children) were: high‐risk group (HGR), by the protocol classification, and less than 10 doses of asparaginase. The increased risk of events and death in HGR, who did less than 10 doses, was 3.6 and 7 times, respectively. The study did not show statistical significance for the number of asparaginase doses in patients who were not at high risk.Conclusions: We demonstrated that the early interruption of asparaginase treatment could negatively impact the prognosis of patients with ALL, especially HGR, reinforcing the need for careful diagnosis of reactions and the availability of alternative types of asparaginase.
- 13 April 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (4) , 1053-1054
Response to comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions
- 13 April 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (4) , 1053-1054
Response to comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions
- 27 February 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (3) , 551-559
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions
Allergic hypersensitivity reactions related to enzyme asparaginase may occur during intravenous infusion of drugs and other adverse reactions (non-allergic hypersensitivity and hyperammonemia), which do not require discontinuation of therapy as the first case. It makes differential diagnoses between infusion reactions essential to assure the team regarding the right decision to make after the adverse event. This study evaluated a pharmacovigilance strategy of differentiating infusion reactions to asparaginase in pediatric patients, based on the measurement of serum ammonia and the classification of the reactions by clinical symptoms and severity. We included children, diagnosed with ALL, and treated with native Escherichia coli asparaginase in a university hospital. The professional team monitored and evaluated all asparaginase infusions for continuity of treatment (rechallenge), seeing the measurement of serum ammonia and classification of reactions for type and severity grade. Data from this monitoring was collected retrospectively. Chi-square and Mann-Whitney tests were used to compare the ratios between serum ammonia concentration posterior and before asparaginase infusion. 245 infusions in 32 patients were monitored, and 19 reactions were observed in 17 children (53%). Three children have hyperammonemia and continue their treatment. The variation of the serum ammonia levels before and after the infusion was statistically significant, comparing the groups with no reaction or hyperammonemia versus the group with the hypersensitivity reaction. The pharmacovigilance strategy applied in the hospital investigated was a useful and inexpensive tool that supported clinical decision-making and enabled the maintenance of asparaginase therapy for three (9,4%) patients followed up.
- 27 February 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (3) , 551-559
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions
Allergic hypersensitivity reactions related to enzyme asparaginase may occur during intravenous infusion of drugs and other adverse reactions (non-allergic hypersensitivity and hyperammonemia), which do not require discontinuation of therapy as the first case. It makes differential diagnoses between infusion reactions essential to assure the team regarding the right decision to make after the adverse event. This study evaluated a pharmacovigilance strategy of differentiating infusion reactions to asparaginase in pediatric patients, based on the measurement of serum ammonia and the classification of the reactions by clinical symptoms and severity. We included children, diagnosed with ALL, and treated with native Escherichia coli asparaginase in a university hospital. The professional team monitored and evaluated all asparaginase infusions for continuity of treatment (rechallenge), seeing the measurement of serum ammonia and classification of reactions for type and severity grade. Data from this monitoring was collected retrospectively. Chi-square and Mann-Whitney tests were used to compare the ratios between serum ammonia concentration posterior and before asparaginase infusion. 245 infusions in 32 patients were monitored, and 19 reactions were observed in 17 children (53%). Three children have hyperammonemia and continue their treatment. The variation of the serum ammonia levels before and after the infusion was statistically significant, comparing the groups with no reaction or hyperammonemia versus the group with the hypersensitivity reaction. The pharmacovigilance strategy applied in the hospital investigated was a useful and inexpensive tool that supported clinical decision-making and enabled the maintenance of asparaginase therapy for three (9,4%) patients followed up.
- Open Access
- 1 October 2017
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 39 (4) , 337-342
Reactions related to asparaginase infusion in a 10-year retrospective cohort
- 1 October 2017
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 39 (4) , 337-342
Open AccessReactions related to asparaginase infusion in a 10-year retrospective cohort